| A role for GLUT3 in glioblastoma cell invasion that is not recapitulated by GLUT1 CJ Libby, S Gc, GA Benavides, JL Fisher, SE Williford, S Zhang, AN Tran, ... Cell adhesion & migration 15 (1), 101-115, 2021 | 25 | 2021 |
| Considerations and challenges for sex-aware drug repurposing JL Fisher, EF Jones, VL Flanary, AS Williams, EJ Ramsey, BN Lasseigne Biology of sex Differences 13 (1), 13, 2022 | 11 | 2022 |
| CINmetrics: an R package for analyzing copy number aberrations as a measure of chromosomal instability VH Oza, JL Fisher, R Darji, BN Lasseigne PeerJ 11, e15244, 2023 | 6 | 2023 |
| Computational Advancements in Cancer Combination Therapy Prediction VL Flanary, JL Fisher, EJ Wilk, TC Howton, BN Lasseigne JCO Precision Oncology 7, e2300261, 2023 | 3 | 2023 |
| Evaluating cancer cell line and patient-derived xenograft recapitulation of tumor and non-diseased tissue gene expression profiles BNL Avery S. Williams, Elizabeth J. Wilk, Jennifer L. Fisher bioRxiv, 2023 | 2* | 2023 |
| Sex-biased gene expression and gene-regulatory networks of sex-biased adverse event drug targets and drug metabolism genes BNL Jennifer L. Fisher, Amanda D. Clark, Emma F. Jones BMC Pharmacology and Toxicology, 2024 | 1 | 2024 |
| Inferring chromosomal instability from copy number aberrations as a measure of chromosomal instability across human cancers S Taluri, VH Oza, TM Soelter, JL Fisher, BN Lasseigne Cancer Reports 6 (12), e1902, 2023 | 1 | 2023 |
| Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and cystic mouse Pkd2 model gene expression reversion EJ Wilk, TC Howton, JL Fisher, VH Oza, RT Brownlee, KC McPherson, ... Molecular Medicine 29 (1), 67, 2023 | 1 | 2023 |
| CINmetrics: An R package for chromosomal instability analysis VH Oza, JL Fisher, R Darji, BN Lasseigne bioRxiv, 2021.11. 15.467294, 2021 | 1 | 2021 |
| Signature reversion of three disease-associated gene signatures prioritizes cancer drug repurposing candidates BNL Jennifer L. Fisher, Elizabeth J. Wilk, Vishal H. Oza, Sam E. Gary ... FEBS Open Bio, 2024 | | 2024 |
| Computational Advancements in Drug Repurposing for Cancer Combination Therapy Prediction VL Flanary, JL Fisher, EJ Wilk, TC Howton, BN Lasseigne Preprints, 2023 | | 2023 |
| Application of Machine Learning and Network Approaches to Prioritize Safe and Efficacious Drug Repurposing Candidates JL Fisher The University of Alabama at Birmingham, 2023 | | 2023 |
| Signature reversion of three disease-associated gene signatures prioritizes cancer drug repurposing candidates JL Fisher, EJ Wilk, VH Oza, TC Howton, VL Flanary, AD Clark, ... bioRxiv, 2023.03. 10.532074, 2023 | | 2023 |
| Prioritized polycystic kidney disease drug targets and repurposing candidates from pre-cystic and cystic mouse model gene expression reversion EJ Wilk, TC Howton, JL Fisher, VH Oza, RT Brownlee, KC McPherson, ... bioRxiv, 2022.12. 02.518863, 2022 | | 2022 |
